Otros idiomas Catalyst Pharmaceuticals, Inc.

Acciones

CPRX

US14888U1016

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
14,89 ^USD	+1,43 %		-1,59 %	-11,42 %

10/04	Un iniciado de Catalyst Pharmaceuticals vendió acciones por valor de 392.000 dólares, según un reciente registro de la SEC	MT
28/03	Un iniciado de Catalyst Pharmaceuticals vendió acciones por valor de 411.000 dólares, según un reciente registro de la SEC	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Santhera dans les chiffres noirs en 2023	25/04
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024	22/04
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	10/04
Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04
Certain Restricted Stock Units of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04
Certain Common Stock of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04/04
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	28/03
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day	28/03
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium	27/03
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	14/03
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	14/03
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States	14/03
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy	13/03
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13/03
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13/03
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	13/03
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals	07/03
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05/03
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05/03
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	29/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Catalyst Pharmaceuticals, Inc.: Escenario optimista

07 de marzo 2023 a las 10:25